DeZwarteRidder schreef op 8 april 2015 21:27:
PM heeft een grote voorkeur voor gokken met frauduleuze/dubieuze aandelen; ANFI, NQ, GTAT en nu CBMG:
===========================================================================
Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
Apr. 7, 2015 11:53 AM ET |
Summary
With paid stock promotion CBMG has achieved an unsustainable $500m valuation, and with $20m in stock sold and insiders stock registered to sell, I expect CBMG will continue to collapse.
CBMG "Car-T" technology was acquired for $1.8m, has experienced patient deaths and is worthless. CBMG recent R&D of just $4.9m makes the $500m valuation clearly absurd.
CBMG founders face dishonesty allegations, are responsible for alleged illegal offshore stem cell clinic, while partnered with John Mattera who is currently serving 11 years in prison for fraud (again).
Multiple accounting and financial integrity issues, CFO and Auditor turnover, "material weaknesses" and "inability to timely file" a full 50% of quarterly SEC filings raises accounting and financial integrity questions.
Assuming CBMG is "real" and generously valuing CBMG on fundamentals show -94.6% near term and imminent downside.
I believe Cellular Biomedicine (NASDAQ:CBMG) is another worthless Chinese reverse merger using paid stock promotion. Detailed research proves CBMG has imminent -87% to -94.6% near-term downside.